A Phase II trial of 8 weeks of degarelix for prostate volume reduction: Efficacy and hormonal recovery.

[1]  W. J. Morris,et al.  Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cance , 2017, International journal of radiation oncology, biology, physics.

[2]  Sang Eun Lee,et al.  Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study , 2015, Prostate international.

[3]  W. Wallace,et al.  A Validated Age-Related Normative Model for Male Total Testosterone Shows Increasing Variance but No Decline after Age 40 Years , 2014, PloS one.

[4]  V. Khoo,et al.  Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  L. Tankó,et al.  Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide , 2012, BJU international.

[6]  P. Hoskin,et al.  Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  Jette Borg,et al.  10-year experience with I-125 prostate brachytherapy at the Princess Margaret Hospital: results for 1,100 patients. , 2011, International journal of radiation oncology, biology, physics.

[8]  F. Vicini,et al.  Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy. , 2011, International journal of radiation oncology, biology, physics.

[9]  K. Wallner,et al.  Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. , 2010, International journal of radiation oncology, biology, physics.

[10]  P. Saylor,et al.  Metabolic complications of androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.

[11]  Howard Pai,et al.  Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. , 2009, International journal of radiation oncology, biology, physics.

[12]  G. Lockwood,et al.  Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer. , 2009, International journal of radiation oncology, biology, physics.

[13]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[14]  N. Mabjeesh,et al.  Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy. , 2007, Urology.

[15]  R. Stock,et al.  The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. , 2007, The Journal of urology.

[16]  K. Wallner,et al.  Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy. , 2006, Urology.

[17]  D. Dearnaley,et al.  Recovery of serum testosterone after neoadjuvant androgen deprivation therapy and radical radiotherapy in localized prostate cancer , 2006, BJU international.

[18]  Louis Potters,et al.  12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. , 2005, The Journal of urology.

[19]  L. Schour,et al.  High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. , 2005, International journal of radiation oncology, biology, physics.

[20]  B. Davis,et al.  Prostate Volume Before and After Permanent Prostate Brachytherapy in Patients Receiving Neoadjuvant Androgen Suppression , 2004, Cancer journal.

[21]  K. Wallner,et al.  Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. , 2004, International journal of radiation oncology, biology, physics.

[22]  A. Henderson,et al.  Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[23]  K. Yoshimura,et al.  Neoadjuvant flutamide monotherapy for locally confined prostate cancer , 2003, International journal of urology : official journal of the Japanese Urological Association.

[24]  F. Vicini,et al.  Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. , 2002, The Journal of urology.

[25]  H M Sandler,et al.  Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. , 2000, Urology.

[26]  P. Arger,et al.  The effect of androgen deprivation on the early changes in prostate volume following transperineal ultrasound guided interstitial therapy for localized carcinoma of the prostate. , 1999, International journal of radiation oncology, biology, physics.

[27]  W Cavanagh,et al.  Use of TRUS to predict pubic arch interference of prostate brachytherapy. , 1999, International journal of radiation oncology, biology, physics.

[28]  É. Vigneault,et al.  Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  D. Grobbee,et al.  Endogenous sex hormones and metabolic syndrome in aging men. , 2005, The Journal of clinical endocrinology and metabolism.

[30]  L. Potters,et al.  Urinary morbidity following ultrasound-guided transperineal prostate seed implantation. , 1999, International journal of radiation oncology, biology, physics.